2024
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options
Mestre-Bach G, Potenza M. Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options. CNS Drugs 2024, 38: 255-265. PMID: 38485889, DOI: 10.1007/s40263-024-01075-2.Peer-Reviewed Original ResearchMeSH KeywordsCompulsive BehaviorFluoxetineHumansParoxetineSelective Serotonin Reuptake InhibitorsSertralineConceptsCompulsive sexual behavior disorderSexual behavior disorderReuptake inhibitorsBehavioral disordersPornography usePharmacological treatmentCo-occurring disordersEmpirical supportSerotonin reuptake inhibitorsCo-occurring conditionsMood stabilizersPsychiatric disordersPsychological therapiesTricyclic antidepressantsGeneralizability of resultsOpioid antagonistSerotonin antagonistsDisordersSerotoninPharmacological optionsPharmacological approachesAntagonistPharmacological therapyNarrative reviewNefazodone
2023
The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna P, Farahdel E, Potenza M, Crowley M. The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder. Expert Opinion On Pharmacotherapy 2023, 24: 835-847. PMID: 37074259, PMCID: PMC10197951, DOI: 10.1080/14656566.2023.2199921.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdolescentAnxiety DisordersChildHumansSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsConceptsSelective serotonin reuptake inhibitorsSelective norepinephrine reuptake inhibitorGeneralized anxiety disorderAnxiety disordersReuptake inhibitorsPediatric generalized anxiety disorderBetter long-term outcomesSecond-line treatmentNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsFirst-line interventionLong-term outcomesCombination of psychotherapyPrevalent psychiatric disordersEvidence-based statePediatric anxiety disordersArt pharmacotherapyModerate effect sizeFunctional outcomeEarly recognitionMood disordersElevated riskPsychiatric disordersBetter outcomesElectronic databases
1998
Olanzapine Augmentation of Fluoxetine in the Treatment of Refractory Obsessive-Compulsive Disorder
Potenza M, Wasylink S, Longhurst J, Epperson C, McDougle C. Olanzapine Augmentation of Fluoxetine in the Treatment of Refractory Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 1998, 18: 423-424.. PMID: 9790164, DOI: 10.1097/00004714-199810000-00014.Peer-Reviewed Original ResearchOlanzapine Augmentation of Fluoxetine in the Treatment of Trichotillomania
POTENZA M, WASYLINK S, EPPERSON C, MCDOUGLE C. Olanzapine Augmentation of Fluoxetine in the Treatment of Trichotillomania. American Journal Of Psychiatry 1998, 155: 1299a-1300. PMID: 9734562, DOI: 10.1176/ajp.155.9.1299a.Peer-Reviewed Original ResearchAdultAntipsychotic AgentsBenzodiazepinesDrug Therapy, CombinationFemaleFluoxetineHumansOlanzapinePirenzepineSelective Serotonin Reuptake InhibitorsTrichotillomania